



# 8% Don't Adhere to Sovaldi Hepatitis C Treatment in CVS Study

September 23, 2014

---

More than 8 percent of patients taking Sovaldi (sofosbuvir), the latest hepatitis C virus drug from Gilead Sciences, do not complete the full 12-week course of treatment, according to a CVS Health Research Institute study [reported by Forbes.com](#).

Pharmacy data collected during the past nine months shows the dropout rate has been roughly four times that observed in clinical trials.

Whether these patients will have to re-start their treatment to cure the virus remains unknown.

However, it is estimated these patients have already incurred health care costs between \$28,000 and \$56,000 each without knowing if they were cured. The \$1,000-per-pill hep C drug boasts up to 90 percent efficacy when taken as directed.

Meanwhile, Gilead's upcoming fixed-dose combination pill of Sovaldi with a drug called ledipasvir is only an eight-week course of treatment. The U.S. Food and Drug Administration will announce an approval decision October 10.

---

© 2026 Smart + Strong All Rights Reserved.

<http://beta.docker.hepmag.com/article/cvs-sovaldi-adherence-study-26200-1442809066>